Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $29.09

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $29.0909.

A number of research analysts recently issued reports on ELAN shares. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. TD Cowen increased their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, KeyCorp lifted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th.

Elanco Animal Health Trading Down 0.1%

NYSE:ELAN opened at $24.48 on Wednesday. The stock has a 50-day simple moving average of $24.64 and a 200-day simple moving average of $23.97. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock has a market cap of $12.23 billion, a P/E ratio of -59.71, a P/E/G ratio of 1.83 and a beta of 1.68. Elanco Animal Health has a 1 year low of $17.51 and a 1 year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter last year, the company earned $0.26 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts anticipate that Elanco Animal Health will post 1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Shiv O’Neill purchased 3,998 shares of the stock in a transaction on Tuesday, August 18th. The stock was bought at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This represents a 4.77% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Robert M. Vanhimbergen purchased 4,200 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares in the company, valued at $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 63,198 shares of company stock valued at $1,473,109. Insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC increased its position in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Elanco Animal Health in the second quarter valued at about $38,000. Root Financial Partners LLC grew its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the fourth quarter worth $41,000. Finally, Bessemer Group Inc. raised its holdings in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after acquiring an additional 525 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.